XML 70 R63.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Segment Information, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Revenue $ 93,973 $ 46,435 $ 205,295 $ 131,498
Cost of revenue 18,157 16,667 53,135 54,035
Research and development 23,669 24,163 72,006 79,761
Sales and marketing 23,470 20,551 70,090 63,184
General and administrative 17,959 17,258 53,144 54,750
Share-based compensation expense (13,257) (13,522) (38,763) (40,778)
Restructuring expense [1]   (193)   (1,917)
Impairment of long-lived assets 0 0 0 (7,205) [1]
Depreciation and amortization expense (3,972) (4,156) (12,348) (13,510)
Other unallocated items [2] (5,950) (5,305) (18,119) (15,928)
Net income (loss) 9,545 (32,097) (45,878) (125,878)
Operating Segments        
Segment Reporting Information [Line Items]        
Revenue 93,973 46,435 205,295 131,498
Cost of revenue 17,303 14,956 49,723 47,740
Research and development 23,669 24,163 72,006 79,761
Sales and marketing 21,832 18,761 65,199 57,804
General and administrative 10,739 9,622 30,372 30,254
Items to reconcile net loss or net income to Adjusted EBITDA [3] 15,176 15,460 44,716 56,110
Adjusted EBITDA [3] 30,671 (11,332) 16,957 (53,840)
Operating Segments | MRD        
Segment Reporting Information [Line Items]        
Revenue 56,788 37,470 150,447 105,380
Cost of revenue 17,303 14,956 49,723 47,740
Research and development 8,956 9,199 26,613 32,168
Sales and marketing 21,832 18,761 65,199 57,804
General and administrative 10,739 9,622 30,372 30,254
Items to reconcile net loss or net income to Adjusted EBITDA [3] 9,007 8,948 26,226 30,737
Adjusted EBITDA [3] 6,965 (6,120) 4,766 (34,668)
Operating Segments | Immune Medicine        
Segment Reporting Information [Line Items]        
Revenue 37,185 8,965 54,848 26,118
Research and development 14,713 14,964 45,393 47,593
Items to reconcile net loss or net income to Adjusted EBITDA [3] 6,169 6,512 18,490 25,373
Adjusted EBITDA [3] 23,706 (5,212) 12,191 (19,172)
Operating Segments | MRD and Immune Medicine        
Segment Reporting Information [Line Items]        
Share-based compensation expense [4] (11,204) (11,111) (32,368) (33,478)
Unallocated Corporate        
Segment Reporting Information [Line Items]        
Other segment items [5] 4,935 5,725 15,754 25,889
Unallocated Corporate | MRD        
Segment Reporting Information [Line Items]        
Other segment items [5]       2,819
Unallocated Corporate | Immune Medicine        
Segment Reporting Information [Line Items]        
Other segment items [5] $ 4,935 $ 5,725 $ 15,754 $ 23,070
[1] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expense.
[2] Represents unallocated expenses and income not included in the measurements reviewed by the CODM to assess each segment's performance.
[3] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[4] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.
[5] For the MRD segment, includes MRD expenses related to the impairment of long-lived assets. For the Immune Medicine segment, includes all Immune Medicine operating expenses, other than research and development expenses.